These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30148543)

  • 21. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
    Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
    BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia.
    Sasako M
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):939-945. PubMed ID: 31661989
    [No Abstract]   [Full Text] [Related]  

  • 25. Esophageal and esophagogastric junction cancers, version 1.2015.
    Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
    J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distant Oncologic Outcome of Patients with Locally Advanced Unresectable and Metastatic Esophageal Cancer after Multimodality Treatment.
    Anghel R; Constantinoiu S; Bacinschi X; Gales L; Toma RV; Trifanescu O
    Chirurgia (Bucur); 2018; 113(1):116-122. PubMed ID: 29509538
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diagnosis and management of gastro-esophageal junction tumor].
    Chevallay M; Jung M; Niclauss N; Morel P; Mönig S
    Rev Med Suisse; 2017 Jun; 13(567):1236-1239. PubMed ID: 28643978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma.
    Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S
    Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach.
    Cellini F; Morganti AG; Di Matteo FM; Mattiucci GC; Valentini V
    Radiat Oncol; 2014 Feb; 9():45. PubMed ID: 24499595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathologic classification of adenocarcinoma of the esophagogastric junction.
    Baldus SE
    Recent Results Cancer Res; 2010; 182():29-38. PubMed ID: 20676869
    [No Abstract]   [Full Text] [Related]  

  • 31. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study.
    Vermeulen BD; Bruggeman L; Bac DJ; Schrauwen RWM; Epping LSM; Scheffer RCH; Tan ACITL; Groenen MJM; Verhoeven RHA; Siersema PD
    Acta Oncol; 2020 Apr; 59(4):410-416. PubMed ID: 32067535
    [No Abstract]   [Full Text] [Related]  

  • 33. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
    Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
    Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staging of adenocarcinoma of the esophagogastric junction: comparison of AJCC 6th and 7th gastric and 7th esophageal staging systems.
    Kim HI; Cheong JH; Song KJ; An JY; Hyung WJ; Noh SH; Kim CB
    Ann Surg Oncol; 2013 Aug; 20(8):2713-20. PubMed ID: 23456315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localized adenocarcinoma of the esophagogastric junction--is there a standard of care?
    Power DG; Reynolds JV
    Cancer Treat Rev; 2010 Aug; 36(5):400-9. PubMed ID: 20117883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
    Cohen DJ; Leichman L
    J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
    Lutz MP; Zalcberg JR; Ducreux M; Adenis A; Allum W; Aust D; Carneiro F; Grabsch HI; Laurent-Puig P; Lordick F; Möhler M; Mönig S; Obermannova R; Piessen G; Riddell A; Röcken C; Roviello F; Schneider PM; Seewald S; Smyth E; van Cutsem E; Verheij M; Wagner AD; Otto F
    Eur J Cancer; 2019 May; 112():1-8. PubMed ID: 30878666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of operation-introducing hyperthermic intraperitoneal chemotherapy on cellular immune function in patients with adenocarcinoma of the esophagogastric junction.
    Nie Z; Huang Y; Li S; Li L
    Asian J Surg; 2022 Jan; 45(1):559-560. PubMed ID: 34656412
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
    Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
    Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.